Cybin D/B/A Helus Pharma (HELP) fair value analysis
Nasdaq · Updated 2026-10-19
HELP price how computed
Valuation status
No fair-value estimate yetHELP has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for HELP yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $10.55
- Sector
- Healthcare
- 12-month range
- $3.87–$14.02
- Market cap
- $771M
- From 52-week high
- -24.8%
- Shares outstanding
- 73.1M
- Rank in Healthcare by quality score
- #293 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Cybin Inc, operating under the brand name Helus Pharma, is a biotechnology company focused on developing and commercializing psychedelic-based therapeutics for mental health conditions. The company operates primarily in Canada and the United States, conducting research and clinical development activities in these regions.
HELP currently ranks #293 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $771M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $1.3M
- Net margin
- -14108.4%
- EPS (TTM)
- $-4.94
- Shares outstanding
- 73.1M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 34 · neutral
- 50-day average
- $12.12
- 200-day average
- $7.57
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-12
- Last 8 quarters vs consensus
- 3 beat, 5 missed
- Quarter by quarter
- 2026-06 ▼ miss (-13.7%)
2026-03 ▲ beat (+1.9%)
2025-12 ▼ miss (-38.8%)
2025-09 ▼ miss (-24.1%)
2025-06 ▲ beat (+12.0%)
2025-03 ▼ miss (-18.7%)
2024-12 ▲ beat (+66.2%)
2024-09 ▼ miss (-214.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 11 buy · 0 hold · 0 sell (11 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $40.4
- Target vs last price
- +282.9%
What our data shows for HELP
- Shares are trading in the middle of their 12-month price range of $3.87–$14.02.
- The 14-day relative strength index sits at a neutral 34.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- HELP's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the HELP conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for HELP show a shift in the 50/200-day trend state from uptrend to mixed this week. This change reflects a weakening of the intermediate-term momentum that had been supporting the healthcare sector stock. The current valuation verdict remains awaiting full valuation.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is HELP stock undervalued?
TickrTrends has no fair-value estimate for HELP yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is HELP's TickrTrends verdict?
HELP is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does HELP compare to other Healthcare stocks?
HELP ranks #293 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is HELP overbought or oversold?
HELP's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does HELP report earnings next?
HELP's next earnings report is scheduled for 2026-11-12, per the published earnings calendar.
Does HELP usually beat earnings estimates?
Over its last 8 reported quarters HELP beat the consensus estimate 3 times and missed 5 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about HELP?
Of 11 analysts covering HELP, 11 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $40.4 (+282.9% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.